The following transcript has been edited for clarity. 

Hi everybody. My name is Patricio G. Schlottmann, MD. I’m a retina specialist from Buenos Aires, Argentina. We’ve just been at the Retina World Congress, where I have presented on the use of ultrawidefield optical coherence tomography angiography (OCTA) to evaluate patients with diabetic retinal disease. That means patients with diabetic retinopathy and also patients with macular edema.

This is of particular interest for those patients that have peripheral disease. The OCTAs that we use—these are devices [made by TowardPi Medical] that are still not licensed in the United States, but we can use them as investigational tools within our country. So we have collected a lot of data, and we have seen that it’s a very good predictor without being invasive. We don’t even need to dilate the pupils of these patients. It’s a great predictor of disease progression, using the OCTA in an ultrawidefield fashion. No dilation, 24-mm images obtained in one go, and it’s really useful for the management of patients with diabetic eye disease. Thank you. RP